Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening.

ABSTRACT:

Background

Epstein-Barr Virus (EBV) latent infection is associated with several human malignancies and is a causal agent of lymphoproliferative diseases during immunosuppression. While inhibitors of herpesvirus DNA polymerases, like gancyclovir, reduce EBV lytic cycle infection, these treatments have limited efficacy for treating latent infection. EBNA1 is an EBV-encoded DNA-binding protein required for viral genome maintenance during latent infection.

Methodology

Here, we report the identification of a new class of small molecules that inhibit EBNA1 DNA binding activity. These compounds were identified by virtual screening of 90,000 low molecular mass compounds using computational docking programs with the solved crystal structure of EBNA1. Four structurally related compoun

SUBMITTER: Li N 

PROVIDER: S-EPMC2853575 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature